Cardiologists at Arnold Palmer Hospital for Children performed Florida’s first pediatric implant of a new device to prevent sudden cardiac arrest.

 Mitralign Inc. has completed enrollment in a study in Europe investigating its lead device, the Mitralign System, in patients with functional mitral regurgitation (FMR).

April 10, 2014 — CardioKinetix Inc. announced results of a pooled analysis study of the catheter-based Parachute ventricular partitioning device. Twelve-month clinical results from 111 consecutive U.S. and European patients with ischemic heart failure were presented at the 2014 annual meeting of the American College of Cardiology (ACC) by Philip Adamson, medical director at the Heart Failure Institute at Oklahoma Heart Hospital.


April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency (RF) ablation in the treatment of non-valvular atrial fibrillation, the addition of three new anticoagulants to treatment options, a diminished role in the use of aspirin and a more comprehensive risk calculator.

April 10, 2014 — Patients presenting to the emergency department with an undetectable level of the blood biomarker high-sensitivity cardiac troponin T, and whose ECGs (electrocardiograms) show no sign of restricted blood flow, have a minimal risk of heart attack within 30 days, according to research presented at the American College of Cardiology’s 63rd annual scientific session and published online in the Journal of the American College of Cardiology.

April 10, 2014 — The largest single-center study of patients implanted with a total artificial heart found the device may help patients in severe heart failure survive until they can receive a heart transplant, according to research presented at the American College of Cardiology’s (ACC) 63rd annual scientific session.

A study with a new ultrasonic scanning technique shows that scanning of the carotid arteries can reveal who is at high risk of being hit by a blood clot. 

LipoScience Inc. announced data showing that patients managed to a target LDL particle (LDL-P) number, as measured by LipoScience's NMR LipoProfile test, achieved a 22 to 25 percent greater reduction in the risk of cardiovascular (CV) events over a three-year period compared to patients who attained LDL cholesterol (LDL-C) targets.

 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now